The Australian cancer treatment technology group GenesisCare has sealed an agreement with Nazca Capital to acquire the whole of IMOncology. It therefore takes a natural step in its expansion throughout Spain and Western Europe following the commencement of operations in the UK twelve months ago.
IMOncology is the leading private supplier of oncological services in Spain, with 12 centers distributed throughout Andalusia, Madrid, Castile La Mancha, the Valencia Autonomous Community and Murcia. A healthcare network that offers radiotherapy services and medical oncology, both at private clinics and through Spain’s National Health Service.
GenesisCare therefore adds 22 centers to its network between the UK and Spain, as well as another 5 that are in the development phase. Australia is the largest supplier of radiotherapy services with 27 centers. It also offers heart care at 80 other clinics throughout the whole country.
The GenesisCare Plan, announced by its CEO, Dan Collins, includes significant investment in recent technologies and cancer treatment techniques to modernize its facilities, as well as the on-going training of its team and the development of new integrated services for cancer treatment in Spain.
Collins states that he is very happy “to work with IMOncology doctors, their teams and their associated hospitals in Spain. Together we can improve the quality of care of the sick and accelerate their access to treatment”.
GenesisCare employs more than 1,700 professionals and participates in nearly one hundred clinical trials in its country of origin. In July 2015, it acquired Cancer Partners UK in the United Kingdom, which it renamed GenesisCare UK.
Last updated: 18|07|2016